Abstract

LeMaitre Vascular will report quarterly results on May 5, 2026 Post Market; consensus points to continued double‑digit revenue and earnings growth, with investors focused on margin sustainability, expense discipline, and the cadence of organic demand across the company’s core product lines.

Market Forecast

For the first quarter of 2026, the market anticipates revenue of 66.53 million US dollars, implying 15.42% year-over-year growth, alongside adjusted EPS of 0.66, up 32.71% year-over-year; EBIT is estimated at 17.27 million US dollars, a 31.34% increase from the prior-year period. With last quarter’s gross margin at 67.48% and net margin at 24.18%, investors look for similar efficiency this quarter, though no explicit gross margin or net margin forecasts were provided in the available data.

The company’s core product portfolio is expected to benefit from steady procedure volumes, pricing discipline, and ongoing commercial execution, supporting sustained mid‑teens top‑line momentum and healthy operating leverage. Segment‑level revenue and year‑over‑year growth expectations were not disclosed in the available forecasts for the current quarter.

Last Quarter Review

In the previous quarter, LeMaitre Vascular delivered revenue of 64.45 million US dollars, up 15.68% year-over-year, a gross margin of 67.48%, GAAP net income attributable to shareholders of 15.58 million US dollars for a net margin of 24.18%, and adjusted EPS of 0.68, up 38.78% year-over-year.

A notable highlight was the across‑the‑board beat versus consensus: revenue exceeded expectations by 1.63 million US dollars, adjusted EPS topped by 0.02, and EBIT surpassed by 0.93 million US dollars, while net profit was down 10.25% sequentially, reflecting normal quarter-to-quarter fluctuations. A detailed revenue breakdown by business line and its year‑over‑year growth was not included in the dataset used here and is therefore not presented.

Current Quarter Outlook

Main business trajectory

The core revenue base is set up for another quarter of double‑digit expansion, with consensus penciling in 15.42% year‑over‑year growth to 66.53 million US dollars and a strong step‑up in profitability per share. The performance algorithm remains straightforward: stable hospital procedure activity, expanded account coverage, disciplined pricing, and contribution from prior commercial investments tend to support consistent volume and price mix. With last quarter’s gross margin at 67.48%, investors’ working assumption is that the mix of higher‑value devices, solid manufacturing yields, and logistics efficiencies can keep margins within a high‑60% area, even without an explicit management gross‑margin target for this quarter.

Operating leverage is a central focus given the forecast EPS growth of 32.71% year‑over‑year against revenue rising 15.42% year‑over‑year. This gap implies a favorable balance between gross margin and operating expense growth, supported by ongoing cost control and scale benefits in selling, general, and administrative activities. As usual, variability in procedure patterns and regional order timing can influence quarterly pacing, but the prior quarter’s results demonstrated that the company can convert top‑line growth into above‑consensus EBIT and EPS, which sets a constructive baseline heading into the print. FX remains a background variable for international sales translation; based on recent commentary across the medtech space, a mixed currency backdrop can cause minor noise, yet the demand trendline appears primarily volume‑driven.

Cash flow quality, while not summarized in the available tool outputs, will be inferred from profitability and working capital discipline. Investors will monitor inventory and receivables turns for confirmation that sales growth is not accompanied by disproportionate working capital build. Capital deployment intentions can also sway sentiment: tuck‑in acquisitions and consistent investment in manufacturing and quality systems typically support sustainable growth and stability in gross margin. Absent an explicit margin guide, the path of adjusted EPS versus revenue will act as the near‑term barometer for the efficiency of the growth model.

Most promising business

Within the product suite, higher‑value implants and specialized devices tend to deliver attractive price‑mix and recurring utilization, making them natural candidates to drive incremental margin. While segment‑level revenue and year‑over‑year growth for the current quarter are not provided in the available dataset, qualitative expectations favor categories that support critical vascular procedures where device performance and reliability command premium positioning. As accounts expand and cross‑selling advances, device families aligned with durable clinical need and consistent utilization patterns should compound faster than the portfolio average.

Analysts also anticipate that product lines with broader geographical availability and supply continuity can post steadier sequential performance. Commercial initiatives that deepen penetration at existing accounts often have a shorter payback versus entering entirely new market categories, suggesting continued emphasis on expanding usage within current call points. In addition, the normalization of hospital staffing and scheduling through the first months of the year can aid utilization for routine vascular procedures, giving these product groups a supportive backdrop. In this context, investors will look for management color on reorder cadence, any new account additions, and the balance between price and volume contributions to growth as the most promising categories extend their run‑rate.

From a profitability standpoint, these product clusters carry meaningful implications for gross margin mix. If sales skew toward categories that carry higher contribution margins, incremental gross profit dollars can outpace revenue growth, reinforcing the operating‑leverage narrative already embedded in consensus EPS. The combination of stable utilization, supportive price mix, and process efficiencies in production would underpin this dynamic. Visibility into backlogs and lead times can further validate the sustainability of demand in these areas.

Key stock price swing factors this quarter

Three variables are likely to drive the share reaction around results: the magnitude of the revenue print versus the 66.53 million US dollars baseline, the quality of the margin profile implied by adjusted EPS of 0.66, and the tone of management’s intra‑quarter commentary on demand and expenses. A revenue beat accompanied by stable or improving gross margin would be consistent with the double‑digit EBIT growth embedded in forecasts and would likely be read as evidence of efficient scaling. Conversely, a revenue in‑line outcome combined with a softer EPS trajectory would imply either a mix shift or higher operating costs, and markets will quickly parse selling, general, and administrative spending and any temporary cost items to understand the underlying trend.

Guidance cadence for the remainder of 2026 is another swing factor. Investors will be sensitive to how management frames the full‑year revenue and operating margin path after a first‑quarter comp that is expected to be healthy. Commentary on the breadth of demand across geographies and procedural types may shape expectations for second‑quarter seasonality and back‑half pacing. Any update on potential tuck‑in deals, portfolio enhancements, or capacity investments can be interpreted as signals of growth confidence, with implications for capital allocation and medium‑term profitability trajectories.

Finally, qualitative items such as hospital ordering patterns, distributor inventory levels, and supply chain stability can cause near‑term volatility if they diverge from prior trends. FX translation could modestly color reported growth, though the demand drivers appear primarily operational rather than currency‑led. Investors will also watch for any comments on pricing discipline and reimbursement dynamics, as these factors influence both near‑term revenue conversion and longer‑term margin durability. Pulling these levers together, the balance of risk and reward into the print hinges on whether the company can deliver the expected mid‑teens revenue growth while defending high‑60% gross margins and translating that into the forecast double‑digit EBIT and EPS increases.

Analyst Opinions

The balance of published views in the recent period is decisively positive, with a 100% bullish skew among covered notes and no bearish calls identified. Stifel Nicolaus reiterated a Buy rating with a 115 US dollars price target, emphasizing confidence in sustained double‑digit revenue growth and the quality of the margin structure. Lake Street Capital maintained a Buy with a 110 US dollars price target, highlighting consistent execution and a runway for operating leverage as selling, general, and administrative expenses scale more slowly than gross profit. Barrington Research reaffirmed an Outperform rating and has cited price targets in the 95–105 US dollars range in recent updates, pointing to robust earnings progression supported by both organic growth and disciplined expense control. Roth MKM initiated/maintained a Buy with a 108 US dollars target, focusing on the resilience of the business model and the prospects for continued EPS expansion.

Across these bullish views, the core thesis clusters around three pillars. The first is revenue durability: analysts expect mid‑teens growth in the near term, in line with the 15.42% year‑over‑year increase embedded in the first‑quarter revenue estimate of 66.53 million US dollars. The second is margin consistency: with last quarter’s gross margin at 67.48% and net margin at 24.18%, the Street anticipates that mix, manufacturing yields, and pricing discipline can protect profitability even as volumes expand, enabling EBIT to grow faster than sales; this underpins the 31.34% year‑over‑year EBIT growth estimate. The third is earnings compounding: the consensus for adjusted EPS at 0.66 implies 32.71% year‑over‑year growth, a rate that, if delivered alongside solid cash conversion, substantiates higher valuation support in the eyes of the bulls.

These institutions also point to potential incremental drivers that could compound beyond the quarter. A sustained pace of commercial expansion, deeper penetration in existing accounts, and periodic portfolio enhancements can broaden the base of recurring usage. If the company’s operating model continues to convert revenue growth into expanding EBIT dollars, as evidenced by the prior quarter’s beats versus consensus, it supports the view that EPS growth can remain ahead of revenue. On the monitoring list, analysts commonly cite expense discipline and gross margin mix as swing variables, but the prevailing expectation is that the business can navigate these while maintaining a growth cadence consistent with or better than current estimates.

Given the unanimity of the recent ratings and the convergence of price targets well above recent trading levels in those reports, the majority stance anticipates a constructive first‑quarter scorecard. Delivery near or above the 66.53 million US dollars revenue estimate with an adjusted EPS outcome close to or exceeding 0.66 would align with the bullish narrative. Clear commentary on demand breadth, operating expense trajectory, and the outlook for the remainder of 2026 would likely be met with a favorable reception from this cohort. In short, the majority view frames the setup as balanced toward positive, contingent on the company defending its high‑margin profile while extending its double‑digit top‑line growth streak in the current quarter.